How to Fight Mental Health & Behavioral Health Insurance Denials

Mental health and behavioral health denials cover a wide range of treatments: inpatient psychiatric hospitalization, residential treatment centers (RTC), partial hospitalization programs (PHP), intensive outpatient programs (IOP), outpatient therapy sessions, transcranial magnetic stimulation (TMS), Spravato (esketamine) infusions, and specialized eating disorder care. Denials in this area are extremely common—insurers routinely cut short inpatient stays after a few days, cap therapy sessions at arbitrary limits, or deny higher levels of care by claiming you can be "safely treated outpatient." The good news: federal parity law (the Mental Health Parity and Addiction Equity Act, MHPAEA) requires insurers to treat mental health conditions the same way they treat physical health conditions, and roughly half of behavioral health denials that reach external independent review are reversed when properly argued.

Why Insurers Deny Mental Health & Behavioral Health Care

Insurers rely on a handful of boilerplate denial templates, often based on their internal guidelines (MCG Behavioral Health, InterQual) or third-party utilization review vendors. Here are the five most common denial reasons you'll see:

1. "Not medically necessary at this level of care"

The insurer claims you can be treated safely at a lower, less expensive level—for example, denying residential treatment and saying you only need PHP, or denying inpatient and saying you can go straight to IOP. This is the most common denial in behavioral health.

2. "Patient stabilized and no longer meets criteria"

For continued-stay denials (days 6–30 of an inpatient admission, or weeks 2–4 of residential), the insurer argues that because your acute suicidal crisis has passed or your vital signs normalized, you no longer need that level of care—even if you remain severely depressed, have not learned any coping skills, and have no discharge plan in place.

3. "Service is experimental / investigational"

Common for TMS and Spravato denials. The insurer claims the treatment lacks sufficient evidence or is not FDA-approved for your specific diagnosis (e.g., denying TMS for bipolar depression or OCD, or Spravato after only one medication trial).

4. "Inadequate trial of outpatient therapy or medication"

The insurer requires you to fail multiple outpatient treatments before authorizing a higher level of care, even when your provider has documented that outpatient treatment failed or that you are in acute crisis.

5. "Session limit / duration cap per policy"

Your plan document says "20 therapy sessions per year" or "30 days residential lifetime maximum," and the insurer applies that limit categorically, regardless of clinical need. This is often a parity violation under MHPAEA if the same hard caps don't apply to, say, physical therapy or chemotherapy.

The Citations Insurers Respect

When you appeal, you need to cite authoritative clinical guidelines and legal frameworks—not just your provider's opinion. Here are the real, named sources that carry weight in mental health appeals. Do not invent citations; use these verbatim when they fit your case.

Federal Parity Law & Legal Precedent

• MHPAEA (Mental Health Parity and Addiction Equity Act, 2008) and the 2024 Final Rule on Non-Quantitative Treatment Limitations (NQTLs) – Requires insurers to treat mental health benefits no more restrictively than medical/surgical benefits.
• Wit v. United Behavioral Health (N.D. Cal. 2019) – Landmark trial-court decision finding that UnitedHealthcare's internal behavioral health guidelines deviated from generally accepted standards of care; widely cited in parity appeals.
• ERISA §502(a) (for employer plans) and 45 CFR §147.136 (ACA external review rights) – Legal basis for your right to appeal and request independent review.

Level-of-Care Criteria

• LOCUS / CALOCUS / CASII (American Association for Community Psychiatry) – Six-dimension level-of-care utilization systems for adults and children; widely recognized as the evidence-based standard for matching patients to the right intensity of care.
• ASAM Criteria, 4th Edition (2023) – The gold standard for substance use disorder (SUD) and dual-diagnosis level-of-care placement; used to determine whether someone needs detox, residential, PHP, IOP, or outpatient.
• MCG Behavioral Health Care Guidelines, 28th Edition – Used by Aetna, Humana, and many Blue Cross Blue Shield plans. If the insurer cited MCG to deny you, obtain the full MCG criteria and show that you do meet them.
• InterQual Behavioral Health Criteria – Used by some BCBS plans and regional insurers; similar strategy—get the criteria and demonstrate you satisfy them.

Diagnosis-Specific Treatment Guidelines

• APA Practice Guidelines: Major Depressive Disorder (MDD), Bipolar Disorder, Schizophrenia (2020), Eating Disorders (4th ed., 2023), Suicidal Behaviors – Published by the American Psychiatric Association; these define evidence-based treatment.
• AACAP Practice Parameters (American Academy of Child and Adolescent Psychiatry) – For adolescent depression, suicidal behavior, eating disorders, and substance use; essential for any denial involving a minor.
• AED Medical Care Standards, 4th Edition (2021) – Academy for Eating Disorders standards; specify medical criteria for inpatient vs. residential vs. PHP for eating disorders (e.g., heart rate <50 bpm, potassium <3.2 mEq/L, severe low BMI).

Evidence for TMS and Spravato

• TMS trials: STARD (Rush et al., 2006), THREE-D trial (Blumberger et al., Lancet* 2018), OPT-TMS (George et al., 2010), Carpenter et al. (2012) showing ~58% response and ~37% remission rates in treatment-resistant depression.
• CMS LCDs for TMS: Novitas LCD L35038, Palmetto LCD L34522 – Medicare local coverage determinations; many commercial insurers defer to these criteria (typically 4–6 weeks at therapeutic dose = failed trial).
• Spravato evidence: TRANSFORM-2 (Popova et al., 2019), SUSTAIN-1 (Daly et al., 2019), ASPIRE I/II (Fu et al., 2020; Ionescu et al., 2021) – FDA registration trials supporting esketamine for treatment-resistant depression and major depressive disorder with suicidal ideation.

How to Argue Against Each Major Denial Reason

1. "Not Medically Necessary at This Level of Care"

What the insurer is really saying: You can be treated at a cheaper level—outpatient instead of IOP, IOP instead of PHP, PHP instead of residential.

How to counter:

• Cite LOCUS/CASII or ASAM Criteria by dimension. These frameworks score six domains (risk of harm, functional status, comorbidity, recovery environment, treatment engagement, resilience). Walk through each dimension and show that you score high enough to require the requested level. For example: "Under LOCUS Dimension 1 (Risk of Harm), patient scores 4 (high risk of suicidal behavior within 24 hours without continuous monitoring); Dimension 3 (Functional Status) scores 4 (unable to perform ADLs, unable to work or attend school)."

• Document failed lower levels of care in the past 12 months. If you tried IOP three months ago and relapsed within two weeks, that proves IOP is insufficient. Cite the APA MDD Guideline recommendation for "step-up" to higher intensity after outpatient failure.

• Highlight acute clinical factors: Active suicidal ideation with plan/intent (positive C-SSRS), severe screening scores (PHQ-9 ≥20, GAD-7 ≥15, MADRS ≥30), psychotic features, medical instability (for eating disorders: bradycardia, electrolyte imbalance), co-occurring substance use. These factors all raise the appropriate level of care.

• Invoke parity: If the insurer would not deny a second week of inpatient medical stabilization for someone with diabetic ketoacidosis who is "medically stable" but not yet safe for discharge, they cannot deny continued psychiatric hospitalization for someone who is no longer in acute suicidal crisis but lacks discharge planning, coping skills, or a safe environment. Request the insurer's comparative analysis under the 2024 MHPAEA Final Rule showing how they apply the same "medical necessity" standard to medical/surgical admissions.

Concrete steps:

1. Get a detailed letter from your psychiatrist or treatment team scoring you on LOCUS/CASII or ASAM dimensions.

2. Attach prior treatment records showing failed outpatient or lower-level attempts.

3. Include your most recent validated screening scores (PHQ-9, C-SSRS, etc.) with dates.

4. In your appeal letter, cite the Wit v. UBH finding that denying care based on "improvement" rather than "readiness for a lower level of care" deviates from generally accepted standards.

5. File the internal appeal within the deadline (typically 180 days for non-urgent, 72 hours for urgent/concurrent review).

---

2. "Patient Stabilized and No Longer Meets Criteria"

What the insurer is really saying: You're not actively suicidal right now, so you can leave the hospital or step down.

How to counter:

• Distinguish "crisis stabilization" from "treatment to remission." The APA Practice Guideline for Suicidal Behaviors and the AACAP parameters emphasize that psychiatric hospitalization should continue until the patient has a workable safety plan, has begun to respond to medication or therapy, and has a safe discharge environment—not just until the immediate crisis passes.

• Cite MCG or InterQual criteria correctly. Many insurers misapply their own guidelines. For example, MCG Behavioral Health 28th ed. continued-stay criteria include "treatment plan modifications in progress" and "barriers to discharge planning unresolved." If your team is still titrating medication, you haven't yet had family sessions, or your home environment is unsafe, you meet continued-stay criteria.

• Document ongoing severity: Even if you're no longer on 1:1 observation, if your PHQ-9 is still 22, you're not sleeping, and you haven't acquired any coping skills, you remain severely ill. Provide updated scores every few days during the appeal.

• Use Wit v. UBH language: The court found that UBH's focus on "acute" symptoms (denying care once someone is not imminently dangerous) contradicts generally accepted standards, which recognize that effective treatment requires time to achieve symptomatic improvement and functional recovery, not just removal of acute risk.

Concrete steps:

1. Request daily or every-other-day clinical updates from your treatment team showing what active treatment is occurring (medication adjustments, therapy milestones, discharge planning gaps).

2. Obtain a letter stating you do not yet meet discharge criteria per LOCUS or the facility's evidence-based protocol.

3. If applicable, document unsafe discharge environment (homelessness, active substance use in the home, lack of outpatient follow-up availability).

4. In your appeal, quote the insurer's own guideline (MCG or InterQual) and show you satisfy it.

5. If the insurer still denies, proceed immediately to external independent review (IRO) and cite parity law.

---

3. "Service Is Experimental / Investigational" (TMS, Spravato)

What the insurer is really saying: We don't want to pay for this expensive treatment.

How to counter (TMS):

• TMS has FDA clearance (2008 for MDD) and is backed by multiple RCTs. Cite: STARD showing that patients who fail 2–4 medication trials have <10% remission with the next drug; OPT-TMS (George 2010) and Carpenter 2012 meta-analysis (~58% response, ~37% remission in treatment-resistant depression); THREE-D trial (Blumberger, Lancet* 2018) showing bilateral TMS superiority.

• Reference Medicare LCDs. Novitas LCD L35038 and Palmetto LCD L34522 both cover TMS for MDD after failure of ≥4 antidepressant trials (or ≥1 trial if intolerant). If Medicare covers it, calling it "experimental" is indefensible.

• If you have a non-MDD diagnosis (bipolar depression, OCD, PTSD): TMS has FDA clearance for OCD (2018). For bipolar depression, cite the emerging evidence (e.g., McGirr 2016 meta-analysis) and argue that off-label use of an FDA-cleared device for a severe, treatment-resistant condition is standard psychiatric practice—analogous to using lithium off-label for unipolar depression.

How to counter (Spravato/esketamine):

• Spravato is FDA-approved for treatment-resistant depression (2019) and MDD with acute suicidal ideation (2020). Cite TRANSFORM-2, SUSTAIN-1, and ASPIRE trials.

• Check the denial's stated reason. Many insurers require ≥2 failed antidepressant trials from different classes at therapeutic doses for ≥6 weeks. Document your medication history in detail (drug, dose, duration, outcome). If you meet this, the denial is simply wrong.

• Parity argument: If the insurer routinely approves expensive oncology drugs after one or two failed chemotherapy regimens, they cannot categorically deny Spravato after the FDA-mandated two failed trials. Request the comparative analysis.

Concrete steps:

1. Obtain a letter from your psychiatrist documenting prior medication trials (names, max doses, durations ≥6–8 weeks, outcomes) and why TMS or Spravato is medically necessary now.

2. Attach published trial references (you can find these on PubMed; include the PMID or DOI).

3. If the insurer cited a specific policy bulletin (e.g., Aetna CPB 0469, Cigna coverage policy), obtain the full text and show you meet the criteria.

4. Appeal internally, then request external review. IRO reviewers in mental health cases often defer to treating psychiatrist + published evidence.

---

4. "Inadequate Trial of Outpatient Therapy or Medication"

What the insurer is really saying: You haven't "earned" a higher level of care yet.

How to counter:

• Acute risk overrides step-therapy. If you have active suicidal ideation with plan/intent, acute psychosis, or severe eating disorder with medical instability (heart rate <50, K⁺ <3.2), the APA and AACAP guidelines are clear: you need the appropriate acute level of care now, not after months of outpatient trials.

• Cite your actual outpatient history. If you have tried outpatient therapy (e.g., 12 sessions of CBT, 16 weeks of medication management) and worsened or failed to improve, document it. The insurer cannot require you to repeat a failed intervention.

• ASAM and LOCUS both allow direct admission to higher levels based on severity, not just failed treatments. ASAM Dimension 1 (acute intoxication/withdrawal risk) and Dimension 2 (biomedical conditions) can drive level-of-care need independent of treatment history.

• Parity: Insurers do not require patients with new-onset chest pain to "fail" outpatient cardiology before authorizing a cardiac cath. Similarly, they cannot require someone in suicidal crisis to fail outpatient therapy before authorizing inpatient or residential care.

Concrete steps:

1. Document the timeline: when outpatient treatment was tried, for how long, with what result (worsening PHQ-9, suicide attempt, hospitalization).

2. If you're in acute crisis, get a letter emphasizing the current risk level (C-SSRS score, plan/means, inability to contract for safety).

3. Cite APA or AACAP guideline language about acute stabilization taking precedence over sequential trials.

4. Frame the denial as an NQTL under MHPAEA—ask the insurer to produce evidence that they impose the same "fail outpatient first" requirement on, say, post-surgical pain management or diabetes education.

---

5. Session Limits / Duration Caps

What the insurer is really saying: Your plan document says "20 visits per year" or "30 days residential lifetime max," so you're done.

How to counter:

• Hard caps are often parity violations. Under MHPAEA and the 2024 Final Rule, if your plan does not impose a similar hard cap on, say, physical therapy visits or chemotherapy cycles, it cannot impose one on mental health. Request the insurer's comparative analysis showing how the limit is applied to medical/surgical benefits.

• Medical necessity should override plan limits when clinically appropriate. Many state parity laws (California SB 855, New York Mental Health Parity Act, Illinois Parity Act) and the ACA's essential health benefits protections require coverage of medically necessary mental health treatment regardless of arbitrary visit caps.

• Cite your ongoing severity. If your PHQ-9 remains ≥15 after 20 sessions, you have not achieved remission. The APA MDD Guideline recommends continuation treatment until sustained remission (typically 4–9 months at full intensity).

Concrete steps:

1. Review your Summary Plan Description (SPD) or Evidence of Coverage (EOC). Look for any mention of session limits.

2. Compare: does the plan cap physical therapy, cardiac rehab, or dialysis sessions? If not, the mental health cap is likely a parity violation.

3. File an internal appeal citing MHPAEA, the 2024 Final Rule, and your state parity law.

4. Request external review. Also consider filing a complaint with your state insurance department and the U.S. Department of Labor (for ERISA plans) or CMS (for ACA marketplace plans).

5. If you're in California, New York, or Illinois, explicitly cite the state parity statute in your appeal.

---

What We Do

We help patients and families draft evidence-based, parity-law-backed appeals in minutes. You answer a few questions about your treatment, diagnosis, and denial reason; we generate a physician-ready appeal letter citing the right clinical guidelines (LOCUS, ASAM, APA, MCG, TMS trials, Spravato evidence), the right legal framework (MHPAEA, Wit v. UBH, state parity laws), and concrete arguments tailored to your insurer. The letter is designed to go straight to your psychiatrist or treatment team for signature, then to the insurer's internal appeals unit and, if necessary, to external independent review. Our mission is to level the playing field—insurers have teams of nurses and lawyers; you deserve the same quality of argument.

---

Sources

1. Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), 29 U.S.C. § 1185a; 42 U.S.C. § 300gg-26.

2. Departments of Labor, HHS, and Treasury. Final Rules on Mental Health Parity and Addiction Equity Act (2024), 89 Fed. Reg. 77,586 (Sept. 23, 2024).

3. Wit v. United Behavioral Health, 2019 WL 1033730 (N.D. Cal. Mar. 5, 2019).

4. American Society of Addiction Medicine. The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions, 4th ed. (2023).

5. American Association for Community Psychiatry. LOCUS / CALOCUS / CASII: Level of Care Utilization System for Psychiatric and Addiction Services (2010–present editions).

6. MCG Health (Hearst). MCG Behavioral Health Care Guidelines, 28th ed. (2024).

7. Change Healthcare (Optum). InterQual Behavioral Health Criteria (current ed.).

8. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. (2010, reaffirmed 2015); Practice Guideline for the Treatment of Patients with Eating Disorders, 4th ed. (2023); Practice Guideline for the Assessment and Treatment of Patients with Suicidal Behaviors (2003, under revision).

9. American Academy of Child and Adolescent Psychiatry. Practice Parameters (various, including adolescent depression, suicidal behavior, substance use disorders).

10. Academy for Eating Disorders (AED). Medical Care Standards Guide for Eating Disorders, 4th ed. (2021).

11. Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report.* Am J Psychiatry 2006;163(11):1905–17. PMID: 17074942.

12. Blumberger DM, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet 2018;391(10131):1683–92. PMID: 29726344.

13. George MS, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 2010;67(5):507–16. PMID: 20439832.

14. Carpenter LL, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety 2012;29(7):587–96. PMID: 22689344.

15. Novitas Solutions. Local Coverage Determination (LCD) L35038, Transcranial Magnetic Stimulation (eff. 2015, rev. 2023).

16. Palmetto GBA. Local Coverage Determination (LCD) L34522, Transcranial Magnetic Stimulation (TMS) (eff. 2013, rev. 2022).

17. Popova V, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 2019;176(6):428–38. PMID: 31109201. (TRANSFORM-2)

18. Daly EJ, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2019;76(9):893–903. PMID: 31141121. (SUSTAIN-1)

19. Fu DJ, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry 2020;81(3):19m13191. PMID: 32316080.

20. Ionescu DF, et al. Effect of esketamine nasal spray plus oral antidepressant treatment on suicidal ideation in patients with major depressive disorder and suicidality (ASPIRE II). Int J Neuropsychopharmacol 2021;24(1):36–46. PMID: 33031529.

21. Employee Retirement Income Security Act of 1974 (ERISA), 29 U.S.C. § 1001 et seq.

22. 45 C.F.R. § 147.136 (Internal claims and appeals and external review processes).

23. California Senate Bill 855 (2020), codified at Cal. Health & Safety Code §§ 1374.72, 1374.73.

24. New York Mental Health Parity Act, N.Y. Ins. Law § 3221(l); N.Y. Mental Hyg. Law § 7.09.

25. Illinois Mental Health Parity Act, 215 ILCS 5/370c.